An expanded access record providing REGN5458 in Multiple Myeloma, sponsored by Regeneron Pharmaceuticals. Approved for marketing. Per ClinicalTrials.gov, last updated 2025-11-10.
Sponsored by Regeneron Pharmaceuticals · Expanded access
Provide Compassionate Use' of REGN5458 for Patients with Relapsed or Refractory Multiple Myeloma
Compassionate Use requests are only being considered in response to Individual Patient Investigational New Drug (IND) applications.
3,632 studies on the registry are indexed under Multiple Myeloma; 745 are open to participants now.
Browse Multiple Myeloma studies →Regeneron Pharmaceuticals is the lead sponsor of 400 studies on the registry; 91 are open to participants now.
Of its 120 completed or terminated interventional studies of FDA-regulated products, 77 (64%) have results posted.
Counted across the registry records on this site, refreshed daily.
-
Exclusion Criteria:
-
Also known as: BCMAxCD3, linvoseltamab
No study locations are listed for this record.
Expanded access is arranged between your doctor and the company. Ask your care team to contact the provider listed on this record.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Regeneron Pharmaceuticals